Back to search results
NCT06656715

Symptom Burden and Health Related Quality of Life of Cancer Patients With Concurrent Heart Failure

Active, Not Recruiting
Not specifiedAges 18+Observational
M.D. Anderson Cancer Center
~102 participants
Updated 2026-07-14 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Heart Failure
Measured over Through study completion, an average of 3 years
+1 more outcome measured

Conditions

Heart Failure

Explore related trials

Heart FailureSolid Neoplasm

NCT06656715

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The University of Texas of MD Anderson Cancer Center

    Houston, Texasno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years and older
Individuals with a concurrent solid tumor cancer diagnosis
Not receiving active cancer treatment except for those on maintenance (i.e., Selective ER modulators (SERMs)\[Tamoxifen\], Aromatase inhibitors (Anastrozole, Letrozole, Exemestane), Ovarian suppression therapy (GnRH Agonists \[Leuprolide\], Androgen deprivation therapy for prostate cancer
Completed cancer treatment at least 3 months and up to 3 years before study enrollment.
Able to read, speak and consent in English
Ability to understand and the willingness to sign a written informed consent document
Diagnosis of heart failure, confirmed by echocardiogram, MUGA, or cardiac catheterization
Internet access via smart phone, tablet, a computer, or another device with the capacity to 1) download the Fitbit App and 2) complete electronic study assessments via REDCap.

Exclusion

Participants undergoing active cancer treatment.
Inability to provide consent in the medical record, such as cognitively impaired individuals.

What this trial measures

  • Heart FailureThrough study completion, an average of 3 years

    The investigators will conduct a symptom assessment at study enrollment on cancer participants with a concurrent diagnosis of HF (HFrEF and HFpEF) using the MD Anderson Symptom Inventory- Heart Failure (MDASI-HF) and PROMIS Instruments (Fatigue, Dyspnea, and Sleep Disturbance).

  • Heart FailureThrough study completion, an average of 3 years

    The investigators will also describe and compare the health-related quality of life using the European Organization for Research and Training Quality- of-Life Questionnaire-Core 30 (EORTC QLQ-C30) and the Measure of Quality of Life Short Form-12 (SF-12).